Vascular Glucose Sensor Symposium

Joseph, Jeffrey I.; Torjman, Marc C.; Strasma, Paul

doi:10.1177/1932296815587938

Cited by 10 publications

(4 citation statements)

References 135 publications

(311 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of the small sample size, their results should be interpreted with caution. Studies on exenatide as an adjuvant to other hypoglycemic agents have generated inconsistent results regarding whether exenatide could reduce GV parameters such as MAGE and SDBG [ 25 , 35 – 37 ]. Therefore, the ability of exenatide to effectively control overall GV is less certain at this point.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial

Wang

Yang³

et al. 2020

Diabetes Ther

View full text Add to dashboard Cite

Introduction: To compare blood glucose variability (GV) in Chinese participants with type 2 diabetes mellitus (T2DM) whose blood glucose levels are inadequately controlled with metformin monotherapy after twice-daily exenatide or biphasic insulin aspart 30 (BIAsp30). Methods: In this 16-week multicenter, randomized clinical trial, 104 participants were randomized 1:1 to receive exenatide (exenatide group) or BIAsp30 (BIAsp30 group) twice daily. All participants continued metformin treatment. The primary outcome was the change in GV as measured by a continuous glucose monitoring system (CGMS) from baseline to 16 weeks. Results: At 16 weeks, both the Exenatide and BIAsp30 groups effectively decreased mean glucose (MG), but neither group changed the mean amplitude of glycemic excursion (MAGE), largest amplitude of glycemic excursion (LAGE), mean of daily difference (MODD), or standard deviation of blood glucose (SDBG). The decrease in 2-h post-breakfast glucose excursions was greater in the Exenatide group compared to the BIAsp30 group, with a least square (LS) mean difference [95% CI] of (1.58 [0.53, 2.63]). Exenatide also significantly reduced 2-h post-lunch Digital Features To view digital features for this article go to

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial

Wang

Yang³

et al. 2020

Diabetes Ther

View full text Add to dashboard Cite

show abstract

“…In all participants, simultaneous monitoring of glucose and Holter ECG was performed. Within 4-day of informed consent, patients underwent CGM using the CGMS (Medtronic iPro2) [ 12 ], and Holter ECG monitoring was introduced 24-h after the start of CGM. CGM and Holter ECG were recorded during the next 48-h in parallel by synchronizing the timing of the devices.…”

Section: Methodsmentioning

confidence: 99%

α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study

Shimabukuro

Tanaka

Sata

et al. 2017

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundLittle is known about clinical associations between glucose fluctuations including hypoglycemia, heart rate variability (HRV), and the activity of the sympathetic nervous system (SNS) in patients with acute phase of acute coronary syndrome (ACS). This pilot study aimed to evaluate the short-term effects of glucose fluctuations on HRV and SNS activity in type 2 diabetes mellitus (T2DM) patients with recent ACS. We also examined the effect of suppressing glucose fluctuations with miglitol on these variables.MethodsThis prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group comparative study included 39 T2DM patients with recent ACS, who were randomly assigned to either a miglitol group (n = 19) or a control group (n = 20). After initial 24-h Holter electrocardiogram (ECG) (Day 1), miglitol was commenced and another 24-h Holter ECG (Day 2) was recorded. In addition, continuous glucose monitoring (CGM) was performed throughout the Holter ECG.ResultsAlthough frequent episodes of subclinical hypoglycemia (≤4.44 mmo/L) during CGM were observed on Day 1 in the both groups (35% of patients in the control group and 31% in the miglitol group), glucose fluctuations were decreased and the minimum glucose level was increased with substantial reduction in the episodes of subclinical hypoglycemia to 7.7% in the miglitol group on Day 2. Holter ECG showed that the mean and maximum heart rate and mean LF/HF were increased on Day 2 in the control group, and these increases were attenuated by miglitol. When divided 24-h time periods into day-time (0700–1800 h), night-time (1800–0000 h), and bed-time (0000–0700 h), we found increased SNS activity during day-time, increased maximum heart rate during night-time, and glucose fluctuations during bed-time, which were attenuated by miglitol treatment.ConclusionsIn T2DM patients with recent ACS, glucose fluctuations with subclinical hypoglycemia were associated with alterations of HRV and SNS activity, which were mitigated by miglitol, suggesting that these pathological relationships may be a residual therapeutic target in such patients. Trial registration Unique Trial Number, UMIN000005874 (https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006929)Electronic supplementary materialThe online version of this article (doi:10.1186/s12933-017-0571-1) contains supplementary material, which is available to authorized users.

show abstract

“…If the patient’s serum glucose concentration is fluctuating, it may be necessary to measure glucose every 30 or 60 min[ 60 ]. Currently, technology for continuous blood glucose monitoring using vascular catheter blood sampling is currently undergoing clinical trials and may become the standard of care and can allow tighter glycemic control in addition to preventing severe hypoglycemia or hyperglycemia[ 61 ]. Research has shown promise, as the technology is capable of detecting changes in glycemia that may otherwise be missed in our current practice, and has shown that glucose levels correlate well with standard arterial glycemic measurement[ 62 - 64 ].…”

Section: Glycemic Control Therapymentioning

confidence: 99%

Management of critically ill patients with diabetes

Silva-Perez

Benitez-Lopez

Varon

et al. 2017

WJD

View full text Add to dashboard Cite

Disorders of glucose homeostasis, such as stress-induced hypoglycemia and hyperglycemia, are common complications in patients in the intensive care unit. Patients with preexisting diabetes mellitus (DM) are more susceptible to hyperglycemia, as well as a higher risk from glucose overcorrection, that may results in severe hypoglycemia. In critically ill patients with DM, it is recommended to maintain a blood glucose range between 140-180 mg/dL. In neurological patients and surgical patients, tighter glycemic control (i.e., 110-140 mg/d) is recommended if hypoglycemia can be properly avoided. There is limited evidence that shows that critically ill diabetic patients with a glycosylated hemoglobin levels above 7% may benefit from looser glycemic control, in order to reduce the risk of hypoglycemia and significant glycemic variability.

show abstract

Vascular Glucose Sensor Symposium

Cited by 10 publications

References 135 publications

Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial

Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial

α-Glucosidase inhibitor miglitol attenuates glucose fluctuation, heart rate variability and sympathetic activity in patients with type 2 diabetes and acute coronary syndrome: a multicenter randomized controlled (MACS) study

Management of critically ill patients with diabetes

Contact Info

Product

Resources

About